Evidence map›Paper›PMID 39090508›Full record

ArticlePharmaceutical medicine2024

Cultivating Excellence: Future-Proofing Medical Affairs with Tailored Talent Programs.

Florian Reis, Neda Rajaeean, Reyhan Rose Divarci, Veit Sollacher, Elke Dworatzek, Daniela Fliegner, Hagen Krüger, Christian Lenz, Clara Craesmeyer

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Florian Reis *Medical Affairs, Pfizer Pharma GmbH, Friedrichstr. 110, 10117, Berlin, Germany.
Neda Rajaeean *Medical Affairs, Pfizer Pharma GmbH, Friedrichstr. 110, 10117, Berlin, Germany.
Reyhan Rose Divarci *Medical Affairs, Pfizer Pharma GmbH, Friedrichstr. 110, 10117, Berlin, Germany.
Veit SollacherMedical Affairs, Pfizer Pharma GmbH, Friedrichstr. 110, 10117, Berlin, Germany. veit.sollacher@pfizer.com.ORCID 0009-0008-6605-2862
Elke DworatzekMedical Affairs, Pfizer Pharma GmbH, Friedrichstr. 110, 10117, Berlin, Germany.
Daniela FliegnerMedical Affairs, Pfizer Pharma GmbH, Friedrichstr. 110, 10117, Berlin, Germany.
Hagen KrügerMedical Affairs, Pfizer Pharma GmbH, Friedrichstr. 110, 10117, Berlin, Germany.
Christian LenzMedical Affairs, Pfizer Pharma GmbH, Friedrichstr. 110, 10117, Berlin, Germany.
Clara CraesmeyerMedical Affairs, Pfizer Pharma GmbH, Friedrichstr. 110, 10117, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In today's rapidly growing healthcare landscape, the role of Medical Affairs within pharmaceutical companies has transitioned from a traditional support function into a strategic one. Amidst acute challenges such as evolving globalization, digitization, and healthcare trends, effective talent development and professional standards in Medical Affairs emerge as a pivotal cornerstone to future-proof pharmaceutical companies. This article explores strategies, perspectives, and best practices for enhancing talent development with medical or natural sciences background in the field of Medical Affairs. From the historical development of Medical Affairs, we cover current challenges and provide a comprehensive approach to talent development strategies of next-generation talents in Medical Affairs. Drawing upon current literature and personal experiences, we discuss various aspects relevant for designing targeted training programs, fostering interdisciplinary collaboration, and enhancing both technical and soft skills essential for success in Medical Affairs roles. Furthermore, we highlight the significance of company-internal rotational programs in exposing talents to different facets of Medical Affairs. We advocate for a flexible and individualized approach to talent development, allowing next-generation talents to pursue personal interests and contribute to innovative projects. Overall, this article offers practical recommendations for pharmaceutical companies aiming to optimize their local talent development initiatives in Medical Affairs and align them with the evolving needs of the healthcare landscape.

Indexed as

Drug IndustryDelivery of Health CareHumans

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.